D
Diana Graus-Porta
Researcher at Novartis
Publications - 28
Citations - 5049
Diana Graus-Porta is an academic researcher from Novartis. The author has contributed to research in topics: Epidermal growth factor & Receptor tyrosine kinase. The author has an hindex of 19, co-authored 28 publications receiving 4776 citations.
Papers
More filters
Journal ArticleDOI
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
TL;DR: Analysis of ErbB receptor interplay induced by the epidermal growth factor (EGF)‐related peptides provides the first biochemical evidence that a given Erb B receptor has distinct signaling properties depending on its dimerization.
Journal ArticleDOI
β1-Class Integrins Regulate the Development of Laminae and Folia in the Cerebral and Cerebellar Cortex
Diana Graus-Porta,Sandra Blaess,Mathias Senften,Amanda Littlewood-Evans,Caroline H. Damsky,Zhen Huang,Paul C. Orban,Rüdiger Klein,Johannes C. Schittny,Ulrich Müller +9 more
TL;DR: The phenotype of the beta1-deficient mice resembles pathological changes observed in human cortical dysplasias, suggesting that defective integrin-mediated signal transduction contributes to the development of some of these diseases.
Journal ArticleDOI
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova,Lecia V. Sequist,Jose Manuel Perez Garcia,Fabrice Andre,Jean-Pierre Delord,Manuel Hidalgo,Jan H.M. Schellens,Philippe A. Cassier,D. Ross Camidge,Martin Schuler,Ulka Vaishampayan,Howard A. Burris,G. Gary Tian,M. Campone,Zev A. Wainberg,Wan-Teck Lim,Patricia LoRusso,Geoffrey I. Shapiro,Katie Parker,Xueying Chen,Somesh Choudhury,Francois Ringeisen,Diana Graus-Porta,Dale Porter,Randi Isaacs,Reinhard Buettner,Jürgen Wolf +26 more
TL;DR: BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
Journal ArticleDOI
Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.
TL;DR: The observations demonstrate that ErbB-2 plays a central role in the type I/EGFR-related family of receptors and that receptor transmodulation represents a crucial step in growth factor signaling.
Journal ArticleDOI
ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
TL;DR: Differential receptor phosphorylation may be the basis for the differences in the signaling properties observed, and tryptic phosphopeptide mapping of both ErbB-1 and ErBB-2 revealed that receptorosphorylation is dependent on the dimerization partner.